Cargando…

Incidence of UL97 Resistance Mutations in Infants with Congenital Cytomegalovirus Disease Receiving 6 Months of Oral Valganciclovir Therapy

BACKGROUND: A recently completed Phase 3 randomized, controlled, double-blind, multicenter study of infants with symptomatic congenital cytomegalovirus (CMV) disease receiving 6 months of oral valganciclovir (VGCV) therapy represents the largest such population in which to evaluate treatment-emergen...

Descripción completa

Detalles Bibliográficos
Autores principales:	James, Scott H, Conner, Ra’Shun L, Kimberlin, David W, Whitley, Richard, Prichard, Mark N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631963/ http://dx.doi.org/10.1093/ofid/ofx162.058

Ejemplares similares

1146. Thrombocytosis in Infants with Congenital Cytomegalovirus Infection Being Treated with Valganciclovir
por: Murtagh, Kathleen, et al.
Publicado: (2020)

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir
por: Ortiz-Gracia, Alba, et al.
Publicado: (2022)

Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection
por: Ohyama, Shohei, et al.
Publicado: (2019)

Human Cytomegalovirus Replication Is Strictly Inhibited by siRNAs Targeting UL54, UL97 or UL122/123 Gene Transcripts
por: Hamilton, Stuart T., et al.
Publicado: (2014)

The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein
por: Shannon-Lowe, Claire D, et al.
Publicado: (2010)

Serine 13 of the human cytomegalovirus viral cyclin-dependent kinase UL97 is required for regulatory protein 14-3-3 binding and UL97 stability
por: Iwahori, Satoko, et al.
Publicado: (2022)

Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
por: Gill, Rachel B, et al.
Publicado: (2009)

The Cyclin-Dependent Kinase Ortholog pUL97 of Human Cytomegalovirus Interacts with Cyclins
por: Graf, Laura, et al.
Publicado: (2013)

Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan
por: Morioka, Ichiro, et al.
Publicado: (2022)

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
por: Kabata, Yoshiaki, et al.
Publicado: (2012)

Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment
por: Torii, Yuka, et al.
Publicado: (2023)

Assessment of the Human Cytomegalovirus UL97 Gene for Identification of Resistance to Ganciclovir in Iranian Immunosuppressed Patients
por: Keyvani, Hossein, et al.
Publicado: (2016)

Polymorphisms and features of cytomegalovirus UL144 and UL146 in congenitally infected neonates with hepatic involvement
por: Guo, Gangqiang, et al.
Publicado: (2017)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
por: Patil, A Jayaprakash, et al.
Publicado: (2010)

The Cytomegalovirus Protein Kinase pUL97: Host Interactions, Regulatory Mechanisms and Antiviral Drug Targeting
por: Steingruber, Mirjam, et al.
Publicado: (2020)

Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis
por: Tamura, Satoshi, et al.
Publicado: (2021)

Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-Generation Sequencing
por: Lodding, Isabelle P, et al.
Publicado: (2021)

Recombinant Human Cytomegalovirus Expressing an Analog-Sensitive Kinase pUL97 as Novel Tool for Functional Analyses
por: Krämer, Nadine, et al.
Publicado: (2022)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

Efficacy and safety of valganciclovir in patients with symptomatic congenital cytomegalovirus disease: Study Protocol Clinical Trial (SPIRIT Compliant)
por: Morioka, Ichiro, et al.
Publicado: (2020)

The Interaction between Cyclin B1 and Cytomegalovirus Protein Kinase pUL97 is Determined by an Active Kinase Domain
por: Steingruber, Mirjam, et al.
Publicado: (2015)

Human Cytomegalovirus Nuclear Capsids Associate with the Core Nuclear Egress Complex and the Viral Protein Kinase pUL97
por: Milbradt, Jens, et al.
Publicado: (2018)

1584. Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-generation Sequencing
por: Lodding, Isabelle Paula, et al.
Publicado: (2018)

Functional Relevance of the Interaction between Human Cyclins and the Cytomegalovirus-Encoded CDK-Like Protein Kinase pUL97
por: Schütz, Martin, et al.
Publicado: (2021)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation
por: Rissling, Olesja, et al.
Publicado: (2018)

Congenital Cytomegalovirus infection: advances and challenges in diagnosis, prevention and treatment
por: Marsico, Concetta, et al.
Publicado: (2017)

Proteomic Interaction Patterns between Human Cyclins, the Cyclin-Dependent Kinase Ortholog pUL97 and Additional Cytomegalovirus Proteins
por: Steingruber, Mirjam, et al.
Publicado: (2016)

Characterization of human cytomegalovirus UL145 and UL136 genes in low-passage clinical isolates from infected Chinese infants
por: Wang, Bo, et al.
Publicado: (2011)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

Long-Term Clinical, Audiological, Visual, Neurocognitive and Behavioral Outcome in Children With Symptomatic and Asymptomatic Congenital Cytomegalovirus Infection Treated With Valganciclovir
por: Turriziani Colonna, Arianna, et al.
Publicado: (2020)

Human cytomegalovirus pUL97 upregulates SOCS3 expression via transcription factor RFX7 in neural progenitor cells
por: Wang, Xian-Zhang, et al.
Publicado: (2023)

The Human Cytomegalovirus UL76 Gene Regulates the Level of Expression of the UL77 Gene
por: Isomura, Hiroki, et al.
Publicado: (2010)

The Role of the Human Cytomegalovirus UL133-UL138 Gene Locus in Latency and Reactivation
por: Mlera, Luwanika, et al.
Publicado: (2020)

Characterization of the transcripts of human cytomegalovirus UL144
por: He, Rong, et al.
Publicado: (2011)

Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice
por: Prichard, Mark N, et al.
Publicado: (2006)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014)

The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2019)

Incidence of Ganciclovir Resistance in CMV-positive Renal Transplant Recipients and its Association with UL97 Gene Mutations
por: Aslani, Hamid Reza, et al.
Publicado: (2017)

Analysis of Ganciclovir-Resistant Cytomegalovirus Infection Caused by the UL97 Gene Mutation in Codons 460 and 520 in Pediatric Patients: A Case Series
por: Boonsathorn, Sophida, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a00n1vk6dfdlhfsvdost7e2hjv